PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31319147-2	2019	Here we described the development and specific targeting of daunorubicin (DNR)-loaded CD123/CD33 dual-antibody modified liposome, CD123/CD33-LP-DNR.	Daunorubicin	60-72	interleukin 3 receptor subunit alpha	Homo sapiens	86-91	
31319147-2	2019	Here we described the development and specific targeting of daunorubicin (DNR)-loaded CD123/CD33 dual-antibody modified liposome, CD123/CD33-LP-DNR.	Daunorubicin	60-72	interleukin 3 receptor subunit alpha	Homo sapiens	130-135	
31319147-2	2019	Here we described the development and specific targeting of daunorubicin (DNR)-loaded CD123/CD33 dual-antibody modified liposome, CD123/CD33-LP-DNR.	Daunorubicin	74-77	interleukin 3 receptor subunit alpha	Homo sapiens	86-91	
31319147-2	2019	Here we described the development and specific targeting of daunorubicin (DNR)-loaded CD123/CD33 dual-antibody modified liposome, CD123/CD33-LP-DNR.	Daunorubicin	74-77	interleukin 3 receptor subunit alpha	Homo sapiens	130-135	
31319147-4	2019	In this study, antibody mixture of CD123 and CD33 (1:1, molar ratio) were thiolated and coupled to Mal-PEG2000-DSPE, then the antibody-Mal-PEG2000-DSPE conjugations were inserted on the DNR-loaded PEGylated liposomes (PEG-LP-DNR) via a post insertion method to prepare CD123/CD33-LP-DNR (antibody/S100PC, molar ratio, 0.06%).	Daunorubicin	186-189	interleukin 3 receptor subunit alpha	Homo sapiens	35-40	
28574300-0	2017	Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia.	Daunorubicin	63-75	interleukin 3 receptor subunit alpha	Homo sapiens	5-10	
28574300-8	2017	Daunorubicin (DNR)-loaded H-CD123-NS demonstrated a 2.45- and 3.22-fold higher cytotoxicity, compared to DNR-loaded NS in NB4 and THP-1 cells, respectively.	Daunorubicin	0-12	interleukin 3 receptor subunit alpha	Homo sapiens	28-33	
28574300-8	2017	Daunorubicin (DNR)-loaded H-CD123-NS demonstrated a 2.45- and 3.22-fold higher cytotoxicity, compared to DNR-loaded NS in NB4 and THP-1 cells, respectively.	Daunorubicin	14-17	interleukin 3 receptor subunit alpha	Homo sapiens	28-33	
28583331-4	2017	On the basis of the daunorubicin (DNR) loaded PEGylated liposomes (DNR-LP), a post-insertion method was applied to covalently attach the anti-CD123 mAb onto the surface of the liposomes to obtain the anti-CD123 mAb modified immunoliposomes (CD123-ILP).	Daunorubicin	20-32	interleukin 3 receptor subunit alpha	Homo sapiens	142-147	
32021192-0	2020	Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment.	Daunorubicin	0-12	interleukin 3 receptor subunit alpha	Homo sapiens	50-55	
32021192-4	2020	Many researches reported high expression of CD123 antigen on high-risk MDS cells, so we constructed a novel drug delivery system comprising daunorubicin-loaded CdTe QDs conjugated with anti-CD123 mAbs (DNR-CdTe-CD123) to develop targeted combination chemotherapy for MDS.	Daunorubicin	140-152	interleukin 3 receptor subunit alpha	Homo sapiens	44-57	
32021192-4	2020	Many researches reported high expression of CD123 antigen on high-risk MDS cells, so we constructed a novel drug delivery system comprising daunorubicin-loaded CdTe QDs conjugated with anti-CD123 mAbs (DNR-CdTe-CD123) to develop targeted combination chemotherapy for MDS.	Daunorubicin	140-152	interleukin 3 receptor subunit alpha	Homo sapiens	44-49	
32021192-4	2020	Many researches reported high expression of CD123 antigen on high-risk MDS cells, so we constructed a novel drug delivery system comprising daunorubicin-loaded CdTe QDs conjugated with anti-CD123 mAbs (DNR-CdTe-CD123) to develop targeted combination chemotherapy for MDS.	Daunorubicin	140-152	interleukin 3 receptor subunit alpha	Homo sapiens	190-195